AAM reflects on anniversary of USMCA

The Association for Accessible Medicines is reflecting on the one-year anniversary of the U.S.-Mexico-Canada Agreement, praising the effect it has had on innovation with generics and biosimilars.

AAM president and CEO Dan Leonard said, "One year ago today, the U.S.-Mexico-Canada Agreement set the standard for a modern trade agreement. By balancing support for pharmaceutical innovation with generic and biosimilar competition, USMCA is a win for companies, health systems, patients and taxpayers. 

"The broad bipartisan support this agreement received in Congress demonstrates the importance of access to medicines as a key component of U.S. trade policy. The Association of Accessible Medicines stands with the Biden Administration, Congress and our trading partners in working to ensure that all future trade agreements reflect this critical balance."